Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer answered questions about. Answering a caller’s query about the stock, Cramer stated: “I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is Amgen.” Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditi ...

Core Insights - Ten large-cap stocks were identified as top performers in the previous week, indicating strong market interest and potential investment opportunities [1] Group 1: Stock Performance - The article highlights the performance of ten large-cap stocks, suggesting they may be valuable additions to investment portfolios [1] - Specific stocks are noted for their significant gains, reflecting positive market sentiment and investor confidence [1] Group 2: Market Trends - The performance of these stocks may indicate broader market trends, suggesting a potential shift in investor focus towards large-cap equities [1] - The article implies that the strong performance of these stocks could influence future investment strategies within the industry [1]

Group 1: FuboTV and Rocket Companies - FuboTV reported a 2.3% year-over-year decline in revenue for Q3 2025, totaling $377.20 million, which exceeded the analyst consensus estimate of $361.33 million [1] - Rocket Companies reported quarterly earnings of 7 cents per share, surpassing the Street estimate of 5 cents, with quarterly revenue of $1.78 billion, beating the consensus estimate of $1.66 billion [1] Group 2: Regeneron Pharmaceuticals - The U.S. FDA approved Regeneron Pharmaceuticals' Eylea HD Injection 8 mg for patients with macular edema following retinal vein occlusion, allowing for dosing every 8 weeks after an initial monthly period [2] - Regeneron Pharmaceuticals shares increased by 5% to close at $737.00 [5] Group 3: Stock Price Movements - Rocket Companies shares decreased by 3.6% to settle at $16.17 [5] - Netflix shares fell by 3.9% to close at $105.67 [5] - FuboTV shares dropped by 5% to close at $3.24 [5]

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $73.9 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. Shares of this biotechnology company have underperformed the broader market over the past year. REGN has declined marginally over this time frame, while the broade ...

Core Insights - The FDA approved Regeneron Pharmaceuticals' Eylea HD for treating macular edema following retinal vein occlusion, allowing for dosing every 8 weeks after an initial monthly period [1][4] - Eylea HD is the first treatment for retinal vein occlusion that can potentially reduce the number of injections by half compared to existing therapies, providing greater flexibility for physicians [3] - The approval was based on the Phase 3 QUASAR trial, which demonstrated non-inferior visual acuity gains for Eylea HD compared to the standard Eylea dosing [4] Product Details - Eylea HD (aflibercept) Injection 8 mg is specifically indicated for patients with retinal vein occlusion [1] - The FDA also approved a monthly dosing option for various conditions including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion [2] - The results from the QUASAR trial were consistent across different types of retinal vein occlusions [5] Manufacturing and Market Impact - Regeneron is coordinating with Catalent Indiana to resolve issues identified during a July 2025 FDA inspection related to the Eylea HD pre-filled syringe [5] - The company plans to submit an application for an alternate manufacturing filler for Eylea HD by January 2026 [6] - Following the FDA approval, Regeneron’s stock price increased by 6.26%, reaching $746.72 [6]

Key Takeaways Regeneron won EC nod to expand Libtayo as adjuvant therapy for high-risk CSCC after surgery and radiation.FDA approved Eylea HD for RVO with dosing up to every eight weeks after an initial monthly period.The agency also cleared a monthly option of Eylea HD across wAMD, DME, DR and RVO for select patients.Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission (EC) has approved label expansion of its PD-1 inhibitor Libtayo (cemiplimab).The EC approved Libtayo as an adjuvan ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [2] Core Insights - Eli Lilly's revenue increased by 52% year-on-year in Q3 2025, driven by GLP-1 drugs, with Tirzepatide's quarterly revenue exceeding $10 billion for the first time, showing a 131% year-on-year growth [4] - Novo Nordisk faced intensified competition in the weight loss drug market, leading to a modest revenue growth of 1% for Ozempic and 6% for Wegovy in Q3 2025, prompting a downward revision of its annual performance guidance [4] - A total of 11 out of 16 companies in the report raised their revenue and/or net profit/EPS forecasts for the year, primarily due to better-than-expected sales of new products [4] Summary by Sections 1. Q3 2025 Performance Review - Eli Lilly's Q3 revenue reached $17.6 billion, with a 62% increase in sales volume, while net prices decreased by 10% [12] - Novo Nordisk's sales revenue for Q3 was 75 billion Danish Kroner, with a net profit decline of 27% [13] - JNJ's pharmaceutical segment achieved revenue of $15.6 billion, with significant contributions from oncology and neurology products [14] - AbbVie reported global sales of $15.8 billion, with notable growth in immunology and neurology sectors [15] - Gilead's revenue for Q3 was $7.3 billion, with a 4% increase in HIV product sales [16] 2. MNC Product Performance in the U.S. Market - The median time for MNC products to reach peak sales in the U.S. market is approximately 8 years, with first-in-class (FIC) products achieving this in about 7 years [4] 3. Revenue and Guidance Adjustments - Eli Lilly raised its full-year revenue guidance from $60-62 billion to $63-63.5 billion [12] - Novo Nordisk revised its revenue growth forecast down from 8%-14% to 8%-11% [13] - JNJ increased its full-year revenue guidance from $93.2-93.6 billion to $93.5-93.9 billion [14]

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema f ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001) Libtayo is the current standard of care in advanced CSCC in Europe, and this approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSW ...

PresentationThato Motlanthe Good day to everyone, and thank you for joining us once again to discuss the MTN Group trading update for the 9 months ended September 2025. Apologies for starting 5 minutes late, but we'll give you the full hour in terms of the call. My name is Thato Motlanthe, I look after Investor Relations at the MTN Group. And on the call with me this afternoon, I've got Ralph Mupita, who is our Group President and CEO; as well as Tsholofelo Molefe, who's our Group CFO. Our trading update ...